Cooley, Skadden Rep Cancer Biotech's $1.7B Go-Public Deal
Cancer and disease-focused biotechnology group Celularity said Friday it's going public through a tie-up with blank-check company GX in a deal valued at $1.7 billion and guided by Cooley and Skadden....To view the full article, register now.
Already a subscriber? Click here to view full article